Literature DB >> 25438919

Relation of right ventricular mass and volume to functional health status in repaired tetralogy of Fallot.

Jimmy C Lu1, Jason T Christensen2, Sunkyung Yu2, Janet E Donohue2, Maryam Ghadimi Mahani3, Prachi P Agarwal4, Adam L Dorfman5.   

Abstract

After repair of tetralogy of Fallot, right ventricular (RV) mass and mass:volume ratio may reflect RV remodeling and adverse outcomes. This study aimed to evaluate the relation of RV mass to functional health status and subsequent adverse RV remodeling and to determine whether RV mass measurement in systole could improve reproducibility. In 53 patients with tetralogy of Fallot (median 29 years old) who previously underwent cardiovascular magnetic resonance and completed the Short Form 36, version 2 (Optum, Eden Prairie, MN), short-axis images were analyzed for RV end-diastolic volume and diastolic and systolic mass, indexed to body surface area. The most recent subsequent cardiovascular magnetic resonance study (before pulmonary valve or conduit replacement) was evaluated for change in RV end-diastolic volume and ejection fraction. Diastolic indexed mass ≥37.3 g/m(2) (odds ratio 7.6, p = 0.02) predicted decreased general health scores. In patients with normal RV ejection fraction, indexed mass correlated with Physical Component Summary and general health scores. RV diastolic mass:volume ratio >0.2 had a strong association with subsequent increase in RV end-diastolic volume (odds ratio 26.1, p = 0.002). Systolic RV mass measurement had excellent correlation with diastolic measurement (r = 0.97, p <0.0001), but did not improve intraobserver or interobserver variability. In conclusion, RV mass relates to functional health status and adverse RV remodeling and can be measured with good reproducibility. RV mass should be routinely evaluated in this population and is best measured in diastole; further study is necessary to evaluate longitudinal changes in functional health status and RV parameters.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25438919     DOI: 10.1016/j.amjcard.2014.09.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Assessment of the precision and reproducibility of ventricular volume, function, and mass measurements with ferumoxytol-enhanced 4D flow MRI.

Authors:  Kate Hanneman; Aya Kino; Joseph Y Cheng; Marcus T Alley; Shreyas S Vasanawala
Journal:  J Magn Reson Imaging       Date:  2016-02-12       Impact factor: 4.813

2.  Reproducibility and Agreement of Tissue Tracking versus Feature Tracking for Strain Measurement on Cardiac MR Images in Patients with Repaired Tetralogy of Fallot.

Authors:  Jimmy C Lu; Sowmya Balasubramanian; Sunkyung Yu; Maryam Ghadimi Mahani; Prachi P Agarwal; Adam L Dorfman
Journal:  Radiol Cardiothorac Imaging       Date:  2019-04-25

Review 3.  The value of myocardial strain imaging in the evaluation of patients with repaired Tetralogy of Fallot: a review of the literature.

Authors:  Panagiotis Zachos; Vasilios Nevras; Nikias Milaras; Maria Karakosta; Alkistis Kalesi; Nearchos Kasinos; Antonios Destounis; Nikolaos L Kelekis; Ignatios Ikonomidis; Dimitrios Niakas
Journal:  Heart Fail Rev       Date:  2022-03-14       Impact factor: 4.214

4.  Quality of life in adults with repaired tetralogy of Fallot.

Authors:  Natalia Dłużniewska; Piotr Podolec; Maria Olszowska; Piotr Weryński; Bogdan Suder; Grzegorz Kopeć; Lidia Tomkiewicz-Pająk
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-06-25

5.  Semiautomatic Three-Dimensional Threshold-Based Cardiac Computed Tomography Ventricular Volumetry in Repaired Tetralogy of Fallot: Comparison with Cardiac Magnetic Resonance Imaging.

Authors:  Hyun Woo Goo
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

6.  Comparison between Three-Dimensional Navigator-Gated Whole-Heart MRI and Two-Dimensional Cine MRI in Quantifying Ventricular Volumes.

Authors:  Hyun Woo Goo
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.